Peripheral Arterial Disease Management
Antiplatelet Therapy
- The American College of Cardiology recommends single antiplatelet therapy, specifically clopidogrel 75 mg daily or aspirin 75-160 mg daily, for all patients with symptomatic Peripheral Arterial Disease (PAD) 1, 2, 3
- Clopidogrel 75 mg daily is the first-choice antiplatelet agent, showing a 24% relative risk reduction in cardiovascular events compared to aspirin in PAD patients 2
- Aspirin 75-325 mg daily is recommended if clopidogrel is contraindicated, unavailable, or not tolerated, with a strength of evidence based on guidelines from the European Heart Journal and the Journal of the American College of Cardiology 1, 2, 3
Lipid Management
- The European Heart Journal recommends high-intensity statin therapy for all PAD patients, regardless of baseline cholesterol levels, with a target LDL-C <70 mg/dL 2
- Statins reduce the incidence of intermittent claudication, improve exercise duration, and reduce cardiovascular mortality in PAD patients, as supported by guidelines from the European Heart Journal 2
Blood Pressure Management
- The American College of Cardiology recommends discharge of all PAD patients on antihypertensive therapy with a target BP <140/90 mmHg (or <130/80 mmHg if diabetes or chronic kidney disease is present) 2
- ACE inhibitors or ARBs are the preferred first-line antihypertensive agents for cardiovascular protection in PAD, as recommended by the American College of Cardiology and the European Heart Journal 2
Diabetes Management
- The American College of Cardiology recommends optimizing glycemic control with target HbA1C <7% using glucose-lowering agents with proven cardiovascular benefits, such as GLP-1 receptor agonists or SGLT-2 inhibitors, for PAD patients with diabetes 1, 3
- Prioritize agents with proven cardiovascular benefits over those without such evidence, as recommended by the European Heart Journal and the American College of Cardiology 1
Smoking Cessation
- The American College of Cardiology recommends offering pharmacological therapy for smoking cessation, such as varenicline, bupropion, or nicotine replacement therapy, to all smokers with PAD 2, 3
- Smoking cessation is the single most important intervention to prevent PAD progression, as supported by guidelines from the Journal of the American College of Cardiology and the European Heart Journal 3
Symptom Relief
- The American College of Cardiology recommends adding cilostazol 100 mg twice daily if claudication persists despite 3 months of optimal medical therapy and supervised exercise therapy, with a contraindication in patients with heart failure of any severity 2, 3
- Cilostazol improves symptoms and increases walking distance in PAD patients, as supported by guidelines from the Journal of the American College of Cardiology and the European Heart Journal 3
Post-Revascularization Antiplatelet Therapy
- The European Heart Journal recommends continuing long-term single antiplatelet therapy, such as aspirin 75-100 mg daily or clopidogrel 75 mg daily, after any revascularization procedure (endovascular or surgical bypass) 1, 2
- Dual antiplatelet therapy is not routinely recommended post-revascularization unless there is a specific high-risk indication, as recommended by the European Heart Journal and the American College of Cardiology 1, 2
Medications to Avoid
- The American College of Cardiology recommends avoiding warfarin monotherapy or warfarin plus antiplatelet therapy, unless a separate indication exists, due to increased bleeding risk without cardiovascular benefit 2, 3
- Ticagrelor is not routinely recommended for PAD, as supported by guidelines from the European Heart Journal and the American College of Cardiology 1